Abstract:Introduction: The mammalian target of rapamycin (mTOR) is a serine/ threonine kinase, which is the key component of two distinct signaling complexes in cells; these complexes are the mTOR complex 1 (mTORC1) and the mTOR complex 2 (mTORC2). Given the importance of these complexes in cellular growth, survival, motility, proliferation, protein synthesis and transcription, it is not surprising that they are impacted in multiple types of cancer. Studies on a number of ATP-competitive mTOR inhibitors have suggested that these inhibitors have a therapeutic superiority to rapalogs (rapamycin analogs) in a number of cancers. Areas covered: This review provides insight into the binding of mTOR inhibitors with the ATP-binding site, for the benefit of future mTOR inhibitor design and discovery. The authors, furthermore, deduce that a hypothetical binding mode is from docking studies, co-crystal structures and the structure-activity relationships (SARs). The authors also highlight the preclinical and clinical development of hit/lead compounds, and the selectivity for representative mTOR inhibitors. Expert opinion: The structural analysis of mTOR is hampered by its large size and complexity. Further exploration of mTOR inhibitors may therefore require the combination of structure-based drug design (SBDD, based on the mTOR homology models), fragment-based drug design (FBDD) and analog synthesis. Recent studies suggested that the global inhibition of PI3Ks may be harmful to organisms. Therefore, the future discovery of dual mTOR/PI3K inhibitors needs to ensure that inhibitors are both efficacious and have reduced adverse effects.

Targeting phosphatases: From molecule design to clinical trials

Development of small-molecule inhibitors that target PI3Kβ

Development of small-molecule inhibitors that target PI3K13

Small Molecules Targeting Phosphoinositide 3-Kinases

Drugging Protein Tyrosine Phosphatases through Targeted Protein Degradation

From Tyrosine Kinases to Tyrosine Phosphatases: New Therapeutic Targets in Cancers and Beyond

Targeting Protein Phosphatases for the Treatment of Chronic Liver Disease

Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment.

Small Molecule Substrate Phosphorylation Site Inhibitors of Protein Kinases: Approaches and Challenges

A strategy to disentangle direct and indirect effects on (de)phosphorylation by chemical modulators of the phosphatase PP1 in complex cellular contexts

Targeting cancer with small molecule kinase inhibitors

Heterobifunctional molecules tackle targeted protein dephosphorylation

Therapeutic potential of targeting protein tyrosine phosphatases in liver diseases

Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond

Phthalimide Conjugations for the Degradation of Oncogenic PI3K

Structure-Based Discovery of Small Molecule Inhibitors Targeted to Protein Tyrosine Phosphatase 1B

Protein tyrosine phosphatase inhibitors: a patent review and update (2012–2023)

Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance

Synthetic approaches and clinical application of representative small-molecule inhibitors of phosphodiesterase

Structure-Based Design and Synthesis of Small Molecule Protein-Tyrosine Phosphatase 1b Inhibitors

Targeted protein degradation in cancers: Orthodox PROTACs and beyond